Trending
Europe is pushing back on Washington's chip warDelayed N1trn Stabilisation Fund deepens credit crisisQuantum computers will supercharge the worldScreenworks appoints Lisa Rose as CEOGoogle's new payment policies are a preview of what could come to Apple platformsStar Fox's day one update detailed (UPDATE)Forward Sioux Falls Helps Fill the Gap, Provides Augustana Social Work Students With Paid InternshipsLos Angeles Names a New Schools Superintendent After ScandalGovernment flags illegal ‘Sabhuku Deals’, says only Ministry of Lands can issue offer lettersB.C. teacher accepts 10-year ban over inappropriate relationship with studentNY Fed's Marchioni calls new FOMC reserves language cleanup, not a Warsh policy shiftElectricity: 655m still in darkness as WHO, partners warn of Global Energy, health crisisorder goes live on SmythsMattel’s Hot Wheels rakes in $2.5b as adult collectors take overThese Xgimi Home Projectors Are a Steal With Our Exclusive Prime Day Discount CodesEurope is pushing back on Washington's chip warDelayed N1trn Stabilisation Fund deepens credit crisisQuantum computers will supercharge the worldScreenworks appoints Lisa Rose as CEOGoogle's new payment policies are a preview of what could come to Apple platformsStar Fox's day one update detailed (UPDATE)Forward Sioux Falls Helps Fill the Gap, Provides Augustana Social Work Students With Paid InternshipsLos Angeles Names a New Schools Superintendent After ScandalGovernment flags illegal ‘Sabhuku Deals’, says only Ministry of Lands can issue offer lettersB.C. teacher accepts 10-year ban over inappropriate relationship with studentNY Fed's Marchioni calls new FOMC reserves language cleanup, not a Warsh policy shiftElectricity: 655m still in darkness as WHO, partners warn of Global Energy, health crisisorder goes live on SmythsMattel’s Hot Wheels rakes in $2.5b as adult collectors take overThese Xgimi Home Projectors Are a Steal With Our Exclusive Prime Day Discount Codes

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

Exclusive license and commercialization agreement includes a significant profit share of gross margin from product sales in addition to an…......

News Desk

Staff Writer

Published

Jun 25, 2026

Source

LENZ Therapeutics

Analytics

0 0 0
LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

AI Insight:This deal marks a significant expansion for VIZZ™ in the Australasian market, with substantial profit-sharing potential for both companies.

LENZ Therapeutics and Arrotex Pharmaceuticals have announced an exclusive license and commercialization agreement for VIZZ™ in Australia and New Zealand. This strategic partnership grants Arrotex the rights to commercialize VIZZ™ in the designated region, with a significant profit share of gross margin from product sales. In addition to the profit-sharing arrangement, the agreement outlines a comprehensive framework for the commercialization of VIZZ™, encompassing marketing, sales, and distribution strategies tailored to the Australasian market. The partnership is poised to drive growth for both companies, with Arrotex leveraging its established presence in Australia and New Zealand to maximize the potential of VIZZ™. The deal is a testament to the growing demand for innovative treatments in the region and underscores the companies' commitment to collaborative partnerships in the pursuit of healthcare excellence.